43 results
Page 2 of 3
SUPPL
lcdonubvjeox
10 Dec 19
Supplemental materials (foreign)
4:31pm
SUPPL
6hr9uezf5rkao
9 Dec 19
Supplemental materials (foreign)
6:35am
SUPPL
fqyf29yuxts5r
13 Sep 19
Supplemental materials (foreign)
5:05pm
6-K
EX-99.2
3bg3l13ks
31 May 19
Notice of Annual General Meeting of Shareholders
8:26am
40-F
EX-99.1
5hpp2
19 Mar 19
Annual report (Canada)
4:16pm
SUPPL
wvsjj11nte
30 Nov 18
Supplemental materials (foreign)
5:23pm
6-K/A
EX-99.3
phhlbr6qvmvb
17 May 18
Current report (foreign) (amended)
12:00am
6-K
EX-99.1
ge9jmkn7 0c
21 Nov 16
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
qoyv12abdotk96 lb
21 Nov 16
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
EX-99.1
lt771h2
24 Oct 16
Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings
12:00am
6-K
EX-99.1
m8a9y277 jkz
9 Feb 15
Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers
12:00am
6-K
EX-99.3
7oiatn2 kk
15 Aug 14
Aurinia Reports Second Quarter 2014 Financial Results
12:00am
40FR12B/A
EX-99.27
mwdh52 t6kcu9ymfs
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.15
z17 40oli94dyn9gi25
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.26
2hkndnu10tsp
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.29
1ls57cb zn8v1
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.16
dhsjgam3 0ele1qa
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.42
12u mp02bmjiegat4o
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.24
591d4grha qj5zg7z21
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am
40FR12B/A
EX-99.25
2hg9ff7q4 xfc0on
19 Jun 14
Initial registration of securities (Canada) (amended)
12:00am